Key Takeaways
- The global inhalable biologics market is projected to grow from USD 3.21 billion in 2023 to USD 10.84 billion by 2031, driven by rising respiratory diseases and a demand for non-invasive treatments.
- Innovations in inhalation technology and self-administration trends are enhancing patient experience and treatment effectiveness, particularly in managing conditions like asthma and COPD.
- North America currently dominates the market, while the Asia-Pacific region is anticipated to experience the fastest growth due to improved healthcare access and an expanding pharmaceutical industry.
Market Insights
Kings Research has released a detailed report on the global inhalable biologics market, indicating a significant projected growth from USD 3,210 million in 2023 to USD 10,844.5 million by 2031, reflecting a compound annual growth rate (CAGR) of 16.56% from 2024 to 2031. The growth is attributed to several factors, notably the rising rates of respiratory diseases and the increasing preference for non-invasive drug delivery systems.
Inhalable biologics include therapies such as proteins, antibodies, and vaccines delivered through the lungs. These options are favored over traditional injectables due to their targeted delivery, faster action, and better patient adherence. The industry is rapidly evolving, bolstered by technological advancements in inhalation devices and a shift towards self-administered treatments.
Recent clinical trials demonstrate the promising potential of these therapies. Notable studies include a 48-week trial focused on the inhaled drug molgramostim and a 52-week study on GB0139, a dry powder inhaled medicine. Furthermore, a Phase 2b/3 trial is exploring the effects of AV-101, an inhaled treatment for pulmonary arterial hypertension.
Several key factors are fueling growth in the inhalable biologics market:
– Advancements in dry powder inhaler (DPI) technology are boosting stability and delivery efficiency, enhancing patient-friendliness.
– The rise of peptide-based therapies is expanding treatment options for respiratory and metabolic diseases.
– Growing trends toward self-administration allow patients greater convenience and freedom, with studies indicating high adherence rates among patients using inhalable biologics for asthma.
The increasing prevalence of respiratory diseases, such as asthma and COPD, is also a crucial driver for this market, along with continuous technological enhancements that improve treatment efficacy and patient compliance.
From a decision-maker perspective, the inhalable biologics market promises benefits such as increased efficiency, cost savings through reduced hospital visits, and enhanced compliance. Noteworthy players in the industry include AstraZeneca, MannKind Corporation, and Pulmocide, all of which are focusing on strategic partnerships and product launches.
Regionally, North America commands the largest market share, accounting for 37.47% in 2023, primarily due to its advanced healthcare infrastructure. In contrast, the Asia-Pacific region is poised for rapid growth, propelled by enhanced healthcare access and a burgeoning pharmaceutical sector in countries like India and China.
For further insights, Kings Research offers a detailed report encompassing product types, indications, delivery mechanisms, and geographical factors.
The content above is a summary. For more details, see the source article.
